Rare disease patients face a number of unique challenges and complexities of their conditions, Often, this means that their families and advocates are more engaged with the scientific and research community in comparison to some other disease and patient focus groups. By collaborating with rare disease patients, their families and various stakeholders involved on the design, positioning and subsequent enrollment of clinical trials, studies can be completed faster and more efficiently. PRA Health Sciences' Scott Schliebner (Vice President, Rare Diseases, Scientific Affairs) and Altair da Silva (Senior Manager, Patient Access and Recruitment Services) are joined by Neil Weisman (Executive Vice President and General Manager at Blue Chip Marketing) to discuss the patient voice and the importance of patient and caregiver insight.
Evidence-Based and Site Focused Strategies to Enhance Clinical Trial Enrollment
Evidence-Based and Site-Focused Strategies to Enhance Clinical Trial Enrollment
Risk-Based Approach to Clinical Development
PRA’s risk-based approach to clinical development represents a comprehensive approach to clinical study risk management and includes centralized…
Ask the Experts: What Improvements are Being Made for Psoriasis Treatments?
October 29 is World Psoriasis Day, an annual day devoted to people with psoriasis/psoriatic arthritis. It is a day that was started by psoriasis…